Naoto T Ueno, Director of the University of Hawaii Cancer Center, shared a post on X:
“Tumors resistant to one ADC can regain sensitivity to another ADC with a different payload. Our work shows payload choice-not just target expression-may extend clinical benefit in breast cancer. No evidence that sequential of FDA approved drugs are beneficial in the clinical setting.”
Title: Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer
Authors: Dileep Reddy Rampa, Minji Seo, Nanae Ogata, Zhaoxuan Yang, Nithya Sridhar, Fujii Takeo, Chalothorn Wannaphut, Jennifer A. Maynard, Kyoji Tsuchikama, George W. Sledge, Naoto T. Ueno, Jangsoon Lee
Read The Full Article
More posts featuring Naoto T Ueno on OncoDaily.